protocol for treatment of choroidal neovascularization associated to myopia magna intravitreal bevacizumab

• Conditions: choroidal neovascularization associated to myopia magna; MedDRA version: 14.1Level: LLTClassification code 10060837Term: Choroidal neovascularizationSystem Organ Class: 10015919 - Eye disorders; Therapeutic area: Diseases [C] - Eye Diseases [C11]

• Registration Number: EUCTR2012-001781-15-ES
• Lead Sponsor: IOBA, Universidad de Valladolid

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2012-05-29
• Last Update Posted: 14 August 2012

Recruitment & Eligibility

• Status: Authorised-recruitment may be ongoing or finished
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1-Myopic patients over 18 years with active subfoveal choroidal neovascularisation associated to yuxtafoveolar myopia confirmed by AGF and OCT.
2-Patients with loss of visual acuity less than 6 months lenght caused by the neovascular lesion at the discretion of the researcher.
3-Lesions in which the presence of atrophic or fibrotic component does not prevent vision improvement .
4-4-Patients with active subfoveal and yuxtafoveolar choroidal neovascularization associated with myopia magna previously treated with photodynamic therapy.
5-Informed written consent.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 100
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 10

Exclusion Criteria

1-Previous surgery vitrectomy.
2-tractional maculopathy and/or idiopathic epiretinal membrane diagnosed by OCT.
3-media opacity that does not allow to adequately assess the fundus of the eye.
4-Lack of integrity of the posterior lens capsule in pseudophakia.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified